

INFORMATION DISCLOSURE STATEMENT

Complete if known

Application Number: 09/623,035

21

Filing Date: October 12, 2000

First Named Inventor: Linda Gillian Durrant, et al.

Group Art Unit: 1642

Examiner Name: Misook Yu, Ph.D.

Our File No. 0380-P02284US0

SHEET 1 OF 2

UNITED STATES PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	PATENT NUMBER	ISSUE DATE MM-DD-YYYY	FIRST NAMED INVENTOR

FOREIGN PATENT DOCUMENTS


EXAMINER'S INITIALS	CITE NO.	DOCUMENT NUMBER	COUNTRY OR REGION	DATE OF PUBLICATION MM-DD-YYYY	FIRST NAMED INVENTOR OR APPLICANT
	B1	WO 97/41440	PCT	11-06-1997	Rijksuniversiteit Te Leiden

OTHER PRIOR ART - NON-PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	Include name of the author (in Capital Letters), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
<i>md</i>	C1	LU, J., et al., "Use of Two Predictive Algorithms of the World Wide Web for the Identification of Tumor-reactive T-Cell Epitopes"; Cancer Research, 60: 5223-5227 (2000)
	C2	Pages from the http://www.bmi-heidelberg.com/syfpethi/ website <i>Printed on 19/03/02</i>
	C3	SOUTHWOOD, S., et al., "Several Common HLA-DR Types Share Largely Overlapping Peptide Binding Repertoires"; J. Immunol., 160: 3363-3373 (1998)
	C4	D'AMARO, J., et al., "A Computer Program for Predicting Possible Cytotoxic T Lymphocyte Epitopes Based on HLA Class I Peptide-Binding Motifs"; Human Immunology 43: 13-18 (1995)
	C5	DAVENPORT, M.P., et al., "An empirical method for the prediction of T-cell epitopes"; Immunogenetics 42: 392-397 (1995)
	C6	ZUGEL, U., et al., "Termination of Peripheral Tolerance to a T Cell Epitope by Heteroclitic Antigen Analogues"; J. Immunol., 161: 1705-1709 (1998)
	C7	IRVINE, K. R., et al., "Recombinant Virus Vaccination against "Self" Antigens Using Anchor-fixed Immunogens"; Cancer Research, 59: 2536-2540 (1999)
	C8	OVERWIJK, W.W., et al., "Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4+ T lymphocytes"; PNAS Online, Immunology 96: 2982-2987 (1999)
	C9	ROSENBERG, S.A., et al., "Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma"; Nature Medicine, 4: 321-327

EXAMINER'S SIGNATURE	DATE CONSIDERED
<i>Misook Yu</i>	11-07-03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw a line through citation if citation not in conformance and reference not considered. Include a copy of this form with next communication to applicant.

 <p style="text-align: center;">INFORMATION DISCLOSURE STATEMENT</p>	Complete if known	
	Application Number: 09/623,035	
	Filing Date: October 12, 2000	
	First Named Inventor: Linda Gillian Durrant, et al.	
	Group Art Unit: 1642	
	Examiner Name: Misook Yu, Ph.D.	
SHEET 2 OF 2		Our File No. 0380-P02284US0

my	C10	✓	JAGER, E., et al., "Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers"; PNAS 97: 12198-12203 (2000)
↓	C11	✓	MARCHAND, M, et al., "Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1"; Int. J. Cancer, 80: 219-230 (1999)
↓	C12	✓	TOES, R.E.M., et al., "CD4 T cells and their role in antitumor immune responses"; J. of Experimental Medicine 189: 753-756 (1999)
↓	C13	✓	COULIE, P.G., et al., "A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3"; Proc Natl Acad Sci, USA, 98: 10290-10295 (2001) [Abstract]

EXAMINER'S SIGNATURE	<i>Misook Yu</i>	DATE CONSIDERED	11-07-03
-------------------------	------------------	--------------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw a line through citation if citation not in conformance and reference not considered. Include a copy of this form with next communication to applicant.